SGPSpyGlass Pharma Inc

NASDAQ · Pharmaceuticals · Pharmaceuticals

$24.52-7.12%Market cap840.27M
Latest Close
$24.52
30-Day Move
-7.1%
Market Cap
$840M
Shares Outstanding
31,910,000
Latest Revenue
$0

Analyst consensus: Buy · 9 analysts

NASDAQ:SGPPharmaceuticals / PharmaceuticalsDelayed public snapshot

SpyGlass Pharma Inc

A read-only Alphactor snapshot forSpyGlass Pharma Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.

Snapshot as of2026-04-20

Topline snapshot

Latest Close

$24.52

30-Day Move

-7.1%

Market Cap

$840M

Shares Outstanding

31,910,000

Latest Revenue

$0

Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot

$24.52

-7.1%last 90 delayed daily bars

Market cap$840M

90D High

$32.44

90D Low

$20.15

Avg Volume

138,954

What stands out

SGP is down 7.1% over the last 30 trading days shown on this page.

Latest operating income is $-14M, which helps anchor the headline ratios with an actual earnings figure.

Research snapshot

Dark Pool Short %

79.4%

Fundamentals snapshot

Latest Close

$24.52

30-Day Move

-7.1%

Market Cap

$840M

Shares Outstanding

31,910,000

Latest Revenue

$0

Financial statement snapshot

Revenue

$0

Gross Profit

--

Operating Income

$-14M

Net Income

$-13M

Gross Margin

--

Net Margin

--

Current Ratio

--

Debt / Equity

--

Quality snapshot

Altman Z

0.94

Distress

Piotroski

4

Moderate (4-6)

Cash Conversion

0.82x

Rule of 40

--

Insufficient data

Annual financial history

Annual performance mix

PeriodRevenueOperating IncomeNet IncomeFree Cash Flow
2023-12-31$0$-14M$-13M$-12M
2024-12-31$0$-27M$-29M$-24M
2025-12-31$0$-41M$-40M$-33M

After signup

The app opens the full statement deep dive

Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.

Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.

Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.

Sign up to open the full statements
Dark-pool activity snapshot
Analyst consensus?
Rating(?)

4.44

Consensus

Buy
Target Mean(?)

Target High(?)

Target Low(?)

Analysts

9

Premium previews

See where the deeper analysis goes next

Sign up free
Open a preview card to sample a premium module.

High-intent actions

What you can do after signup

Organic traffic stays on the free tier by default, but signing up lets you save work and continue exploring.

For informational and educational purposes only. Not financial advice. Learn more

For informational and educational purposes only. Not financial advice. Learn more